{
    "Trade/Device Name(s)": [
        "HemosIL Antithrombin"
    ],
    "Submitter Information": "Instrumentation Laboratory Company",
    "510(k) Number": "K070301",
    "Predicate Device Reference 510(k) Number(s)": [
        "K980499"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "JBQ"
    ],
    "Summary Letter Date": "February 23, 2007",
    "Summary Letter Received Date": "January 31, 2007",
    "Submission Date": "January 30, 2007",
    "Regulation Number(s)": [
        "21 CFR 864.7060"
    ],
    "Regulation Name(s)": [
        "Antithrombin III Assay"
    ],
    "Analyte Class(es)": [
        "coagulation"
    ],
    "Analyte(s)": [
        "Antithrombin"
    ],
    "Specimen Type(s)": [
        "Plasma"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [],
    "Method(s)/Technology(ies)": [],
    "Methodologies": [],
    "Submission Type(s)": [
        "Assay",
        "Test"
    ],
    "Document Summary": "FDA 510(k) summary for HemosIL Antithrombin assay for quantitative determination of antithrombin in human plasma.",
    "Indications for Use Summary": "In vitro diagnostic test for quantitative determination of antithrombin in human plasma to monitor heparin therapy in thrombosis and aid diagnosis of congenital antithrombin deficiency (thrombophilia).",
    "fda_folder": "Hematology"
}